JP2001514663A - アルツハイマー病を処置または予防するための方法 - Google Patents

アルツハイマー病を処置または予防するための方法

Info

Publication number
JP2001514663A
JP2001514663A JP53974498A JP53974498A JP2001514663A JP 2001514663 A JP2001514663 A JP 2001514663A JP 53974498 A JP53974498 A JP 53974498A JP 53974498 A JP53974498 A JP 53974498A JP 2001514663 A JP2001514663 A JP 2001514663A
Authority
JP
Japan
Prior art keywords
insulin
food
disease
agent
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53974498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514663A5 (https=
Inventor
ロバート ダブリュー． エスモンド，
アール ワンズ，ジャック
ラ モンテ，スザンヌ デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001514663A publication Critical patent/JP2001514663A/ja
Publication of JP2001514663A5 publication Critical patent/JP2001514663A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP53974498A 1997-03-12 1998-03-12 アルツハイマー病を処置または予防するための方法 Pending JP2001514663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3960797P 1997-03-12 1997-03-12
US60/039,607 1997-03-12
PCT/US1998/004731 WO1998039967A1 (en) 1997-03-12 1998-03-12 A method for treating or preventing alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009148356A Division JP2009280586A (ja) 1997-03-12 2009-06-23 アルツハイマー病を処置または予防するための方法

Publications (2)

Publication Number Publication Date
JP2001514663A true JP2001514663A (ja) 2001-09-11
JP2001514663A5 JP2001514663A5 (https=) 2005-11-10

Family

ID=21906390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53974498A Pending JP2001514663A (ja) 1997-03-12 1998-03-12 アルツハイマー病を処置または予防するための方法
JP2009148356A Pending JP2009280586A (ja) 1997-03-12 2009-06-23 アルツハイマー病を処置または予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009148356A Pending JP2009280586A (ja) 1997-03-12 2009-06-23 アルツハイマー病を処置または予防するための方法

Country Status (6)

Country Link
US (3) US7300927B2 (https=)
EP (1) EP1006794B1 (https=)
JP (2) JP2001514663A (https=)
CA (1) CA2323889A1 (https=)
DE (1) DE69838789T2 (https=)
WO (1) WO1998039967A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043443A (ja) * 2002-05-14 2004-02-12 Kumamoto Technology & Industry Foundation アミロイドーシスの予防及び治療のための医薬
JP2012500004A (ja) * 2008-08-12 2012-01-05 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
WO2019004321A1 (ja) * 2017-06-28 2019-01-03 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
US11021751B2 (en) 2008-08-12 2021-06-01 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2000043006A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001257451A1 (en) 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
ATE476188T1 (de) * 2002-05-14 2010-08-15 Nipro Corp Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
AU2003274052A1 (en) * 2002-11-12 2004-06-03 L'oreal Use of cellulose microbeads to make the skin matt
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US20090088367A1 (en) * 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8114847B2 (en) 2005-03-16 2012-02-14 Case Western Reserve University Selective inhibitors of translesion DNA replication
WO2008147454A1 (en) 2006-11-16 2008-12-04 Case Western Reserve University Selective inhibitors of translesion dna replication
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
CA2853992C (en) 2007-07-31 2020-06-23 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090216178A1 (en) * 2008-02-26 2009-08-27 Lee Susan J Method And Apparatus For Preventing Localized Stasis Of Cerebrospinal Fluid
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
AU2009266869B2 (en) * 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
US9988680B2 (en) 2011-09-01 2018-06-05 Case Western Reserve University Non-natural nucleosides as theranostic agents
US9821173B2 (en) 2013-02-08 2017-11-21 Case Western Reserve University Anti-cancer agents and methods of use
KR101642042B1 (ko) * 2013-10-24 2016-07-22 건국대학교 글로컬산학협력단 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US5039665A (en) * 1980-07-21 1991-08-13 Markov Angel K Use of fructose-1,6-diphosphate for treating myocardial infarction
US4546095A (en) * 1980-07-21 1985-10-08 Markov Angel K Use of fructose-1,6-diphosphate for treating myocardial infarction
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4757052A (en) * 1982-09-03 1988-07-12 Markov Angel K Method of preserving blood
US4775665A (en) * 1983-05-16 1988-10-04 Massachusetts Institute Of Technology Method and composition for treating neurological disorders and aging
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4703040A (en) * 1985-04-03 1987-10-27 Markov Angel K Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP)
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
US5039794A (en) * 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
NL8800823A (nl) * 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4980350A (en) * 1988-02-25 1990-12-25 Merck & Co., Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
EP0526598B1 (en) * 1990-04-27 1996-12-18 Orion-Yhtymà„ Oy New pharmacologically active catechol derivatives
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
FI930772A0 (fi) * 1990-08-23 1993-02-22 Pfizer Hydroxiureaderivat som saenker glugosnivao i blodet
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5714470A (en) * 1991-08-22 1998-02-03 Merrell Pharmaceuticals, Inc. Orally-active elastase inhibitors
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
EP0915090A1 (en) * 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
FI954738A7 (fi) * 1993-04-06 1995-12-05 Abbott Lab Tetrasykliini yhdisteet dopamiiniagonisteina
KR100392244B1 (ko) 1993-04-20 2003-11-28 더 제너럴 호스피탈 코포레이션 신경사단백질유전자발현및알쯔하이머병의검출
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5395822A (en) * 1993-09-20 1995-03-07 Izumi; Yukitoshi Use of pyruvate to prevent neuronal degeneration associated with ischemia
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
JPH09511492A (ja) * 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
JPH07238035A (ja) * 1994-02-28 1995-09-12 Kyowa Hakko Kogyo Co Ltd βアミロイド蛋白質分解剤
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
AU3146495A (en) 1994-07-22 1996-02-22 Eastern Washington University Methods for stereotactic implantation
US5483070A (en) * 1994-08-02 1996-01-09 Packard Instrument Company Scintillation counter
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
US5602120A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US5618835A (en) * 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
IN182496B (https=) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
GB9627005D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9627006D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
CA2311125C (en) * 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043443A (ja) * 2002-05-14 2004-02-12 Kumamoto Technology & Industry Foundation アミロイドーシスの予防及び治療のための医薬
JP2012500004A (ja) * 2008-08-12 2012-01-05 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
JP2016047058A (ja) * 2008-08-12 2016-04-07 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
JP2018075005A (ja) * 2008-08-12 2018-05-17 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
US10865449B2 (en) 2008-08-12 2020-12-15 Zinfandel Pharmaceuticals, Inc. Method of identifying disease risk factors
US11021751B2 (en) 2008-08-12 2021-06-01 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2019004321A1 (ja) * 2017-06-28 2019-01-03 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
JPWO2019004321A1 (ja) * 2017-06-28 2020-04-30 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
US11554116B2 (en) 2017-06-28 2023-01-17 Kyoto University Agent for preventing and/or treating alzheimer's disease

Also Published As

Publication number Publication date
EP1006794A4 (en) 2004-07-07
JP2009280586A (ja) 2009-12-03
US20040060077A1 (en) 2004-03-25
EP1006794A1 (en) 2000-06-14
DE69838789T2 (de) 2008-10-30
WO1998039967A1 (en) 1998-09-17
US7300927B2 (en) 2007-11-27
DE69838789D1 (de) 2008-01-10
CA2323889A1 (en) 1998-09-17
EP1006794B1 (en) 2007-11-28
US20050043242A1 (en) 2005-02-24
US20090280192A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
JP2001514663A (ja) アルツハイマー病を処置または予防するための方法
US20040058873A1 (en) Method for treating or preventing Alzheimer's disease
Gerich Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus
Lees et al. Deprenyl in Parkinson's disease
US6852760B1 (en) Compositions and methods for treatment for glucose metabolism disorders
JP5595268B2 (ja) メタボリックシンドローム、２型糖尿病、肥満又は糖尿病前症の治療的処置方法
EP3132792B1 (en) Composition and methods for increasing insulin sensitivity
JP6367115B2 (ja) ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
US20060252686A1 (en) Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders
US20050222093A1 (en) Methods for restoring cognitive function following systemic stress
WO2000053171A1 (en) Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
Piccioni et al. Energy drinks: a narrative review of their physiological and pathological effects
Minaker et al. Effect of age on insulin stimulation of sympathetic nervous system activity in man
Ciampelli et al. Insulin and polycystic ovary syndrome: a new look at an old subject
Doelle The clinical picture of metabolic syndrome: an update on this complex of conditions and risk factors
Østoft Incretin hormones and maturity onset diabetes of the young–pathophysiological implications and an-ti-‐diabetic treatment potential
WO2000057721A2 (en) Edible solids for treatment of glucose metabolism disorders
WO2000057729A2 (en) Beverages for treatment of glucose metabolism disorders
Heaney et al. Increased pressor response to noradrenaline in pituitary dependent Cushing's syndrome
US20030144248A1 (en) Surfactant prevention of lung complications from cancer chemotherapy
EP1635804B1 (fr) Utilisation du fer pour le traitement du trouble du deficit de attention/hyper-activite chez les enfants
Kamceva et al. HEREDITARY ANGIOEDEMA (HAE): A CASE REPORT AND LITERATURE OVERVIEW.
Oberlander A Multi-Domain Approach to Prevention and Reversal of Cognitive Decline
Schafmayer et al. Indication and surgical therapy in uncomplicated peptic ulcer disease
Mills et al. Decreased angiotensin II response but unaltered cardiovascular pressor response to infused norepinephrine after sodium restriction and converting enzyme inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050303

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090224